Barely Significant

Excerpts

514,629 sentences

nominally significantp=0.030.6× alphagold
For secondary outcomes Sativex was associated with a nominally significant improvement in hyperactivity/impulsivity (p=0.03) and a cognitive measure of inhibition (p=0.05), and a trend towards improvement for inattention (p=0.10) and EL (p=0.11).
Pharmacological approaches of ADHD
Eur Psychiatry · 2021 · PMC9471268
barely significantp = 0.030.6× alphagold
Using the multivariable time-dependent mixed model we found that, patients on antihypertensive and antihyperlipidemic monotherapy, those that reach the deductible limit are slightly (barely significant) more adherent than those that have not yet reached the deductible limit, with a relative adherence ratio (RAR) of 1.03 (95% CI: 1.00–1.05, p = 0.03) for antihyperlipidemic therapy and 1.02 (95% CI: 1.00–1.04, p = 0.05) for antihypertensive therapy.
Among those with index dates in 1996–2010, differences between the GD subjects and the controls with a history of specialist‐level psychiatric treatment prior to index date appeared quite large but did not reach statistical significance (23.7% vs. 11.8%, p = 0.03).
borderline significanceP = .030.6× alpha
For the MR analysis of the opposite direction (IBD to CHIP), we observed a close to null effect (OR IVW , 0.98; 95% CI, 0.96-1.00) of CD to CHIP with borderline significance ( P = .03; supplemental Table 12 ), compared with the CHIP-to-IBD direction (OR IVW , 1.15; 95% CI, 1.03-1.27), suggesting a potential bidirectional relationship.